BOD Australia (ASX: BDA) has announced they will be supplying a new medicinal cannabis product to a Lambert Initiative sponsored trial on Tourette’s Syndrome, funded by Wesley Medical Research.
Tourette’s Syndrome is a neurological condition characterised by involuntary, irresistible body movements and vocalisations, with studies indicating it affect approximately 0.6% of of children.
The Lambert Initiative was established in 2015 within the University of Sydney following a $33.7 million donation by Barry and Joy Lambert to conduct research on the therapeutic benefits of cannabinoids.
The Initiative has partnered with Dr Philip Mosley from Neurosciences Queensland to study the effects of a 1:1 ratio capsule of THC and CBD on people with Tourette’s Syndrome. The Lamber Initiative is helping source the drug, now known to be supplied by BOD Australia, and perform the analytical toxicology analysis.
This product adds to BOD’s current range, including their flagship product – MediCabilis. All of BOD’s ranges are available under the Special Access Scheme or from an Authorised Prescriber.
BOD’s CEO Jo Patterson said, “Collaborating and supplying an organisation of the Lambert Initiative’s calibre is significant validation of BOD’s product superiority and global uniqueness, as well as the Company’s growing presence in the medicinal cannabis space.
“To have our extracts utilised in an external clinical trial investigating the effects of medicinal cannabis in relation to Tourette’s Syndrome positions BOD exceptionally well for the future. Pending any successful results in relation to this specific condition, BOD will ensure the formulations are made available to eligible patients and approved prescribers under Special Access Scheme Category B. Further, BOD will ensure that it progresses any commercial opportunities which result from the trial, including product development and licensing.”